Experimental HCV Drugs
Experimental HCV Drugs
HCV Polymerase Inhibitor Mericitabine Boosts Interferon/Ribavirin Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 February 2013 00:00
- Written by Liz Highleyman
A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.
Sofosbuvir Combos Match or Beat Standard Hepatitis C Therapy For All Genotypes
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Gilead Sciences
The experimental hepatitis C polymerase inhibitor sofosbuvir in an all-oral regimen with ribavirin worked as well as interferon-based therapy for previously untreated people with HCV genotypes 2 or 3, while adding sofosbuvir to pegylated interferon/ribavirin increased cure rates for those with more difficult-to-treat genotypes, Gilead Sciences announced this week.
Boehringer Ingelheim Starts Phase 3 Trial of Interferon-free Faldaprevir + BI 207127
- Details
- Category: HCV Treatment
- Published on Thursday, 24 January 2013 00:00
- Written by Liz Highleyman
The Phase 3 HCVerso trial, testing an all-oral regimen containing Boehringer Ingelheim's HCV protease inhibitor faldaprevir (formerly BI 201335), polymerase inhibitor BI 207127, and ribavirin has begun enrollment, the company announced last week.
TAG Releases Updated Guide to Hepatitis C Clinical Trials
- Details
- Category: HCV Treatment
- Published on Friday, 01 February 2013 00:00
- Written by Matt Sharp
The Treatment Action Group (TAG) has produced an updated edition of its guide for people considering participating in clinical trials of new therapies for hepatitis C. Written by Matt Sharp and Tracy Swan, the revised Guide to Clinical Trials for People with Hepatitis C provides an overview of the drug development process, along with information about specific types of HCV treatment.
Gilead Provides More Sofosbuvir Data, Plans for Further Hepatitis C Studies
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 January 2013 00:00
- Written by Gilead Sciences
Gilead Sciences this week provided updated results from the ELECTRON trial evaluating sofosbuvir, GS-5885, and ribavirin, coinciding with a presentation at a financial conference in San Francisco. The company also provided information about studies of its sofosbuvir/GS-5885 combination pill now in development.
More Articles...
- Achillion Reports Promising Data on All-oral Hepatitis C Regimen with ACH-3102
- NEJM: Sofosbuvir, ABT-450, ABT-333 Look Good in Interferon-free Hepatitis C Regimens
- Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks
- AASLD 2012: Interferon Lambda Shows Good HCV Suppression, Better Tolerated than Interferon Alfa
Web Design and Development by